Cargando…

Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation

PURPOSE: The aim of this study is to evaluate the efficacy and toxicity of post-operative partial breast re-irradiation with multi-catheter brachytherapy after second breast conserving therapy (BCT) in patients with small, low-risk ipsilateral breast tumor recurrence (IBTR). MATERIAL AND METHODS: Be...

Descripción completa

Detalles Bibliográficos
Autores principales: Forster, Tobias, Akbaba, Sati, Schmitt, Daniela, Krug, David, El Shafie, Rami, Oelmann-Avendano, Jan, Lindel, Katja, König, Laila, Arians, Nathalie, Bernhardt, Denise, Marmé, Frederik, Schneeweiss, Andreas, Heil, Jörg, Sohn, Christof, Debus, Jürgen, Hörner-Rieber, Juliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737570/
https://www.ncbi.nlm.nih.gov/pubmed/31523231
http://dx.doi.org/10.5114/jcb.2019.87001
_version_ 1783450678472998912
author Forster, Tobias
Akbaba, Sati
Schmitt, Daniela
Krug, David
El Shafie, Rami
Oelmann-Avendano, Jan
Lindel, Katja
König, Laila
Arians, Nathalie
Bernhardt, Denise
Marmé, Frederik
Schneeweiss, Andreas
Heil, Jörg
Sohn, Christof
Debus, Jürgen
Hörner-Rieber, Juliane
author_facet Forster, Tobias
Akbaba, Sati
Schmitt, Daniela
Krug, David
El Shafie, Rami
Oelmann-Avendano, Jan
Lindel, Katja
König, Laila
Arians, Nathalie
Bernhardt, Denise
Marmé, Frederik
Schneeweiss, Andreas
Heil, Jörg
Sohn, Christof
Debus, Jürgen
Hörner-Rieber, Juliane
author_sort Forster, Tobias
collection PubMed
description PURPOSE: The aim of this study is to evaluate the efficacy and toxicity of post-operative partial breast re-irradiation with multi-catheter brachytherapy after second breast conserving therapy (BCT) in patients with small, low-risk ipsilateral breast tumor recurrence (IBTR). MATERIAL AND METHODS: Between 2008 and 2018, 19 consecutive patients with low-risk IBTR (max. rpT1 cN0 cM0, Her2 negative, preferably positive hormone receptor status) who refused mastectomy were treated with salvage lumpectomy, followed by post-operative partial breast re-irradiation with multi-catheter brachytherapy. Eight patients were irradiated using PDR brachytherapy (49.8-50.4 Gy in pulses of 0.5-0.7 Gy) and 11 patients using HDR brachytherapy (34.2 Gy in fractions of 3.8 Gy or 32 Gy in fractions of 4 Gy). All patients had undergone prior BCT for their primary tumor, followed by adjuvant whole breast radiotherapy. Local control (LC), locoregional control (LRC), overall survival (OS), disease-free survival (DFS) as well as toxicity were evaluated in the present study. RESULTS: After a median follow-up of 65 months following IBTR (18-120 months), only one second IBTR in 19 patients was diagnosed 77 months after re-irradiation, resulting in a LC rate of 100% at 5 years. DFS and OS rates were both 100% at 5 years following re-irradiation. Except for the above mentioned second IBTR, no regional or distant relapse was recorded. Regarding toxicity, 63% of patients developed adverse events (CTCAE grade ≤ 2), with fibrosis detected in 37% (7/19) of patients, necrosis in 11% (2/19), hyperpigmentation in 47% (9/19), and telangiectasia in 11% (2/19), respectively. No patient showed a high-grade (CTCAE grade ≥ 3) adverse event. CONCLUSIONS: In case of small, low-risk IBTR, adjuvant re-irradiation using multi-catheter brachytherapy is a feasible, safe, and effective treatment method after repeated lumpectomy, and an alternative to mastectomy.
format Online
Article
Text
id pubmed-6737570
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-67375702019-09-13 Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation Forster, Tobias Akbaba, Sati Schmitt, Daniela Krug, David El Shafie, Rami Oelmann-Avendano, Jan Lindel, Katja König, Laila Arians, Nathalie Bernhardt, Denise Marmé, Frederik Schneeweiss, Andreas Heil, Jörg Sohn, Christof Debus, Jürgen Hörner-Rieber, Juliane J Contemp Brachytherapy Original Paper PURPOSE: The aim of this study is to evaluate the efficacy and toxicity of post-operative partial breast re-irradiation with multi-catheter brachytherapy after second breast conserving therapy (BCT) in patients with small, low-risk ipsilateral breast tumor recurrence (IBTR). MATERIAL AND METHODS: Between 2008 and 2018, 19 consecutive patients with low-risk IBTR (max. rpT1 cN0 cM0, Her2 negative, preferably positive hormone receptor status) who refused mastectomy were treated with salvage lumpectomy, followed by post-operative partial breast re-irradiation with multi-catheter brachytherapy. Eight patients were irradiated using PDR brachytherapy (49.8-50.4 Gy in pulses of 0.5-0.7 Gy) and 11 patients using HDR brachytherapy (34.2 Gy in fractions of 3.8 Gy or 32 Gy in fractions of 4 Gy). All patients had undergone prior BCT for their primary tumor, followed by adjuvant whole breast radiotherapy. Local control (LC), locoregional control (LRC), overall survival (OS), disease-free survival (DFS) as well as toxicity were evaluated in the present study. RESULTS: After a median follow-up of 65 months following IBTR (18-120 months), only one second IBTR in 19 patients was diagnosed 77 months after re-irradiation, resulting in a LC rate of 100% at 5 years. DFS and OS rates were both 100% at 5 years following re-irradiation. Except for the above mentioned second IBTR, no regional or distant relapse was recorded. Regarding toxicity, 63% of patients developed adverse events (CTCAE grade ≤ 2), with fibrosis detected in 37% (7/19) of patients, necrosis in 11% (2/19), hyperpigmentation in 47% (9/19), and telangiectasia in 11% (2/19), respectively. No patient showed a high-grade (CTCAE grade ≥ 3) adverse event. CONCLUSIONS: In case of small, low-risk IBTR, adjuvant re-irradiation using multi-catheter brachytherapy is a feasible, safe, and effective treatment method after repeated lumpectomy, and an alternative to mastectomy. Termedia Publishing House 2019-08-29 2019-08 /pmc/articles/PMC6737570/ /pubmed/31523231 http://dx.doi.org/10.5114/jcb.2019.87001 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Forster, Tobias
Akbaba, Sati
Schmitt, Daniela
Krug, David
El Shafie, Rami
Oelmann-Avendano, Jan
Lindel, Katja
König, Laila
Arians, Nathalie
Bernhardt, Denise
Marmé, Frederik
Schneeweiss, Andreas
Heil, Jörg
Sohn, Christof
Debus, Jürgen
Hörner-Rieber, Juliane
Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
title Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
title_full Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
title_fullStr Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
title_full_unstemmed Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
title_short Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
title_sort second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737570/
https://www.ncbi.nlm.nih.gov/pubmed/31523231
http://dx.doi.org/10.5114/jcb.2019.87001
work_keys_str_mv AT forstertobias secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT akbabasati secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT schmittdaniela secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT krugdavid secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT elshafierami secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT oelmannavendanojan secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT lindelkatja secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT koniglaila secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT ariansnathalie secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT bernhardtdenise secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT marmefrederik secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT schneeweissandreas secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT heiljorg secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT sohnchristof secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT debusjurgen secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation
AT hornerrieberjuliane secondbreastconservingtherapyafteripsilateralbreasttumorrecurrencea10yearexperienceofreirradiation